Screener
NewAmsterdam Pharma Company NAMS Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue, current | 2,797 | 3,987 |
| Lease liability, current | 26 | 136 |
| Derivative warrant liabilities | 54,452 | 57,272 |
| Total current liabilities | 72,974 | 85,787 |
| Lease liability, net of current portion | 56 | 66 |
| Total liabilities | 73,030 | 85,853 |
| Commitments and contingencies (Note 12) | ||
| Shareholders' Equity: |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's total current liabilities?
- NewAmsterdam Pharma Company (NAMS) reported total current liabilities of $72.97M in Q2 2026.
- How has NewAmsterdam Pharma Company's total current liabilities changed year-over-year?
- NewAmsterdam Pharma Company's total current liabilities increased by 99.9% year-over-year, from $36.51M to $72.97M.
- What is the long-term trend for NewAmsterdam Pharma Company's total current liabilities?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's total current liabilities has grown at a 33.5% compound annual growth rate (CAGR), from $36.06M to $85.79M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about NewAmsterdam Pharma Company's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude